Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

European Journal of Cancer ◽

10.1016/j.ejca.2016.09.024 ◽

2017 ◽

Vol 70 ◽

pp. 146-155 ◽

Cited By ~ 60

Author(s):

David Miles ◽

David Cameron ◽

Igor Bondarenko ◽

Lyudmila Manzyuk ◽

Juan Carlos Alcedo ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Biomarker Evaluation

A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).

10.1158/0008-5472.sabcs-09-44 ◽

2009 ◽

Cited By ~ 23

Author(s):

W. Gradishar ◽

V. Kaklamani ◽

T. Prasad Sahoo ◽

D. Lokanatha ◽

V. Raina ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Efficacy And Safety ◽

First Line ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy ◽

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

10.1158/0008-5472.sabcs11-s4-8 ◽

2011 ◽

Cited By ~ 19

Author(s):

L Gianni ◽

G Romieu ◽

M Lichinitser ◽

S Serrano ◽

M Mansutti ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

First Results ◽

Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps108 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS108-TPS108 ◽

Cited By ~ 3

Author(s):

W. Parulekar ◽

J. W. Chapman ◽

S. Aparicio ◽

Y. Murray ◽

F. M. Boyle ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Taxane Chemotherapy

Faculty Opinions recommendation of AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717998592.793477025 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC).

10.1158/0008-5472.sabcs-09-41 ◽

2009 ◽

Cited By ~ 15

Author(s):

D. Miles ◽

A. Chan ◽

G. Romieu ◽

L. Dirix ◽

J. Cortés ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Locally Recurrent ◽

First Line Treatment

Abstract P2-16-03: Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer: Overall Survival Results from a Double-Blind, Randomized, Placebo-Controlled, Phase 2b Trial

10.1158/0008-5472.sabcs10-p2-16-03 ◽

2010 ◽

Cited By ~ 3

Author(s):

S Bondarde ◽

V Kaklamani ◽

T Prasad Sahoo ◽

D Lokanatha ◽

V Raina ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

First Line ◽

Double Blind ◽

First Line Therapy ◽

Line Therapy ◽

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Yearbook of Oncology ◽

10.1016/j.yonc.2012.05.013 ◽

2012 ◽

Vol 2012 ◽

pp. 138-139 ◽

Cited By ~ 1

Author(s):

E.G. Chiorean

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study

Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)

10.1158/0008-5472.sabcs12-p5-18-26 ◽

2012 ◽

Cited By ~ 5

Author(s):

SM Swain ◽

S-B Kim ◽

J Cortes ◽

J Ro ◽

V Semiglazov ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps4131 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS4131-TPS4131 ◽

Cited By ~ 4

Author(s):

Charles S. Fuchs ◽

Josep Tabernero ◽

Salah-Eddin Al-Batran ◽

Ian Chau ◽

David H. Ilson ◽

...

Keyword(s):

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study